Frequently asked questions
Which Jenburkt pillar passes the five-pillar test?
Iron Fortress passes. Jenburkt holds net worth of Rs 197.04 cr against borrowings of Rs 2.49 cr, cash of Rs 53.11 cr, a current ratio of about 4.1 and zero promoter pledging, with CRISIL ratings of BBB+ Stable and A2. The reservation is concentration, not solvency: one plant at Sihor makes the range, and Rs 46.12 cr is committed to expanding it.
Why is Jenburkt free cash flow only a partial?
Operating cash flow was strong in the last two years, Rs 27.91 cr in FY25 and Rs 26.52 cr in FY26, but the five year total of Rs 88.87 cr converts only about two thirds of PAT, FY24 delivered just Rs 8.12 cr, and free cash flow after the current expansion capex runs at roughly Rs 8 to 13 cr a year. The spending is named and internal, which keeps the grade at partial rather than fail.
What would change Jenburkt pillar grades?
Sunrise upgrades if sales growth holds in double digits for two straight years. Leadership upgrades on any move to real disclosure, such as a concall, and on promoter buying. Free Cash Flow upgrades on a full year above Rs 25 cr after capex. Iron Fortress downgrades if borrowings rise above Rs 25 cr or the Rs 46.12 cr expansion overruns materially.
How does Jenburkt grade on Sunrise?
PARTIAL. The demand pool is durable: chronic disease prevalence, diagnosis and adherence drive the anti-diabetic, cardiovascular and neuropsychiatry brands Jenburkt leans on, and sales grew every year from Rs 124 cr in FY22 to Rs 169 cr in FY26. The deduction is pace and proof: about 8% compounding and a flat Q1 FY27 at Rs 35.51 cr of sales, partly offset by exports rising to 15.5% of sales in FY26.
How does Jenburkt grade on Leadership?
PARTIAL. The Bhuta family record on what it controls is clean: margins of 22% to 27% for five years, near zero debt, a dividend raised every year from Rs 12.00 to Rs 20.70, no pledging since March 2024 and no dilutive deals. Against that: a promoter stake of 46.62% easing down from 47.56%, no concalls or presentations, no explanation for the Q1 FY27 margin fall, and no public succession discussion.
How does Jenburkt grade on Moat?
PARTIAL. The moat is habit: brands such as Nervijen, Powergesic and Cartisafe Forte prescribed for years by doctors the roughly 700 medical representatives call on, in therapies where patients refill for years. Operating margins of 22% to 27% are the fingerprint. But these are branded generics, with no patent wall, no proprietary API and no regulatory exclusivity, against far larger rivals who can outspend the field force every year.
How does Jenburkt grade on Iron Fortress?
PASS. Net worth of Rs 197.04 cr against borrowings of Rs 2.49 cr and total assets of Rs 226.01 cr. Cash of Rs 53.11 cr, a current ratio of about 4.1, interest near Rs 0.5 cr a year, zero pledging, no subsidiaries and no dilution, with share capital flat at 44.13 lakh shares. The watch item is execution of the Rs 46.12 cr expansion, not survival.
How does Jenburkt grade on Free Cash Flow?
PARTIAL. Operating cash flow of Rs 27.91 cr and Rs 26.52 cr in FY25 and FY26 is genuinely strong, and the Rs 9.13 cr dividend is covered. But five year operating cash flow of Rs 88.87 cr converts only about two thirds of PAT of Rs 139.69 cr, FY24 delivered Rs 8.12 cr, and free cash flow after expansion capex runs at roughly Rs 8 to 13 cr a year while the plant is built.
What is the overall five-pillar verdict?
One of five pass, and the pattern is a quality small business that has not decided to be a bigger one. The fortress passes outright because four decades of restraint built it. Every other pillar waits on the same conversions: the Sihor expansion turning retained cash into operating growth, and management explaining itself when a quarter goes wrong. That is why the companion investment report scores the stock 65/100 Selective Positive: at 1.91x book with a 2.43% yield, the market already charges very little for the conversion.
© 2026 DalalBytes Research · For educational purposes only. Not investment advice.